Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

CVS Caremark has removed coverage of Zepbound, a GLP-1 weight-loss drug, citing pricing concerns and shifting payer dynamics ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year ...

Zepbound led to an average weight loss of 20.2 percent compared to Wegovy's 13.7 percent. We talked with healthcare experts to understand the study's findings, what sets these drugs apart and how ...

Wegovy's maker, Novo Nordisk, is charging $499 per month for its direct-to-consumer product. Customers can't get their health insurance to pay for the either Eli Lilly's Zepbound vials or the ...

"Both Wegovy and Zepbound have demonstrated clinically significant weight reduction." "For example, if a patient has fatty liver, we will choose the GLP-1 that is proven to work best for liver ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

The findings showcased Zepbound's standout efficacy, with participants losing 50.3 lbs on average compared to 33.1 lbs with Wegovy. Additionally, nearly 32 percent of those taking Zepbound ...